PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript March 30, 2026 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.2.
PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focus ...
Greetings, and welcome to PDS Bio Clinical Programs Update Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation.
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results